Analytik Jena will present a range of automation solutions for laboratory workflows at the SLAS 2026 International Conference ...

Analytik Jena will be presenting new automation solutions for laboratory workflows at the SLAS 2026 International Conference & Exhibition (February 7–11). A particular highlight is the launch of the ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher. “Biotech was a coiled spring following several quarters of underperformance,” Dr. Terry Smith, ...

Every year, TechCrunch’s Startup Battlefield pitch contest draws thousands of applicants. We whittle those applications down to the top 200 contenders, and of them, the top 20 compete on the big stage ...

“Biotech is making money again,” Mizuho Securities declared to cap off 2025. The sentiment was echoed across a handful of sector previews as analysts reflected on a turbulent year in life sciences.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

In the fast-paced world of biotechnology, success hinges on more than groundbreaking science—it requires the right connections, strategic partnerships, and access to capital. Biotech Showcase delivers ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Beverly biotech is working ...